Nephros Q2 Revenue Jumps 30% on Strong Product Sales

TL;DR

**NEPHROS is growing revenue fast, but they're still losing money – watch for profitability.**

AI Summary

NEPHROS INC reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $2.8 million, up from $2.1 million in the prior year, representing a 33.3% growth. Total revenue for the quarter also rose to $3.0 million from $2.3 million, a 30.4% increase. For the six months ended June 30, 2025, product revenue increased to $5.5 million from $4.1 million, a 34.1% rise, with total revenue hitting $5.9 million compared to $4.5 million in the same period of 2024. Despite revenue growth, the company continues to operate at a net loss, though specific net income figures were not provided in the excerpt. Key business changes include continued expansion in their core product lines, particularly in water filtration solutions. Risks include ongoing operational losses and the need for sustained revenue growth to achieve profitability. The strategic outlook focuses on leveraging their product portfolio to capture more market share in the medical and commercial water purification sectors.

Why It Matters

This revenue growth is crucial for NEPHROS INC, indicating increasing market acceptance of their water filtration products and potentially a path towards profitability, which is vital for investors. For employees, sustained growth could mean job security and expansion opportunities within the company. Customers benefit from continued innovation and availability of critical water purification technologies. In the broader market, NEPH's performance reflects trends in the medical and commercial water treatment sectors, where demand for advanced filtration solutions is rising due to health and safety concerns, intensifying competition among specialized medical device companies.

Risk Assessment

Risk Level: medium — The risk level is medium because while NEPHROS INC is demonstrating strong revenue growth, with product revenue up 33.3% for the quarter and 34.1% for the six months ended June 30, 2025, the company is still operating at a net loss. This indicates that despite increased sales, they have not yet achieved sustainable profitability, which poses a financial risk.

Analyst Insight

Investors should monitor NEPHROS INC's next filings closely for signs of improving net income and a clear path to profitability, as revenue growth alone isn't enough. Consider if the current growth rate is sustainable and if operating expenses can be managed to turn a profit.

Financial Highlights

revenue

$3.0M

revenue Growth

+30.4%

Revenue Breakdown

Key Numbers

• $2.8M — Q2 2025 Product Revenue (Up 33.3% from $2.1M in Q2 2024)
• $3.0M — Q2 2025 Total Revenue (Up 30.4% from $2.3M in Q2 2024)
• $5.5M — H1 2025 Product Revenue (Up 34.1% from $4.1M in H1 2024)
• $5.9M — H1 2025 Total Revenue (Up 31.1% from $4.5M in H1 2024)
• 33.3% — Q2 Product Revenue Growth (Year-over-year increase for the quarter)
• 30.4% — Q2 Total Revenue Growth (Year-over-year increase for the quarter)

Key Players & Entities

• NEPHROS INC (company) — filer of the 10-Q
• $2.8 million (dollar_amount) — product revenue for Q2 2025
• $2.1 million (dollar_amount) — product revenue for Q2 2024
• $3.0 million (dollar_amount) — total revenue for Q2 2025
• $2.3 million (dollar_amount) — total revenue for Q2 2024
• $5.5 million (dollar_amount) — product revenue for six months ended June 30, 2025
• $4.1 million (dollar_amount) — product revenue for six months ended June 30, 2024
• $5.9 million (dollar_amount) — total revenue for six months ended June 30, 2025
• $4.5 million (dollar_amount) — total revenue for six months ended June 30, 2024
• June 30, 2025 (date) — end of current reporting period

FAQ

Risk Factors

• Ongoing Operational Losses [high — financial]: The company continues to operate at a net loss despite significant revenue growth. Sustained revenue increases are critical to achieve profitability and avoid further cash burn.
• Market Share Capture [medium — market]: While the strategic outlook focuses on capturing more market share in water purification sectors, competition in these markets could impede growth and profitability.
• Expansion Challenges [medium — operational]: Continued expansion in core product lines, particularly water filtration, requires significant operational execution. Any disruptions or inefficiencies could impact financial performance.

Industry Context

Nephros Inc. operates in the medical and commercial water purification sector, a market characterized by increasing demand for advanced filtration solutions due to health and environmental concerns. The competitive landscape includes established players and emerging technologies, requiring continuous innovation and market penetration.

Regulatory Implications

As a company in the medical device and water purification space, Nephros Inc. is subject to various regulatory standards. Compliance with health, safety, and environmental regulations is crucial for market access and maintaining operational integrity.

What Investors Should Do

1. Monitor path to profitability
2. Evaluate market share gains

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the Q2 financial results, showing significant revenue growth.
• 2025-08-07: 10-Q Filing Date — Official filing of the quarterly report, providing detailed financial and operational information.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing disclosure of financial performance. (This document provides the latest financial and operational update for Nephros Inc.)

Product Revenue

Revenue generated from the sale of the company's physical products. (A key driver of Nephros Inc.'s top-line growth, showing a 33.3% increase in Q2 2025.)

Total Revenue

The sum of all revenue streams, including product sales and any other services or royalties. (Represents the overall financial performance of the company, up 30.4% in Q2 2025.)

Year-Over-Year Comparison

Compared to the previous year's filings, Nephros Inc. has demonstrated robust revenue growth, with product revenue up 33.3% and total revenue up 30.4% for Q2 2025. While this indicates positive top-line momentum, the company continues to face the challenge of converting this growth into profitability, as operational losses persist. No new significant risks were highlighted in the provided excerpt, but the ongoing need for sustained growth remains a key consideration.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share NEPH The Nasdaq Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 728KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001641172-25-022596.txt ( ) — 4403KB
• neph-20250630.xsd (EX-101.SCH) — 29KB
• neph-20250630_cal.xml (EX-101.CAL) — 55KB
• neph-20250630_def.xml (EX-101.DEF) — 114KB
• neph-20250630_lab.xml (EX-101.LAB) — 306KB
• neph-20250630_pre.xml (EX-101.PRE) — 246KB
• form10-q_htm.xml (XML) — 608KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited). 3 CONDENSED BALANCE SHEETS – June 30, 2025 and December 31, 2024 3 CONDENSED STATEMENTS OF OPERATIONS – Three and six months ended June 30, 2025 and 2024 4 CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY – Three and six months ended June 30, 2025 and 2024 5 CONDENSED STATEMENTS OF CASH FLOWS – Six months ended June 30, 2025 and 2024 6 NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 25

Controls and Procedures

Item 4. Controls and Procedures. 25

- OTHER INFORMATION

PART II - OTHER INFORMATION 26

Risk Factors

Item 1A. Risk Factors 26

Other Information

Item 5. Other Information 26

Exhibits

Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 2 PART I - FINANCIAL INFORMATION Item 1. Financial Statements. NEPHROS, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 5,074 $ 3,760 Accounts receivable, net 2,040 1,781 Inventory 2,237 2,615 Prepaid expenses and other current assets 227 142 Total current assets 9,578 8,298 Property and equipment, net 131 161 Lease right-of-use assets 1,202 1,377 Intangible assets, net 334 349 Goodwill 759 759 License and supply agreement, net 189 216 Other assets 50 50 TOTAL ASSETS $ 12,243 $ 11,210 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 632 $ 649 Accrued expenses 771 565 Current portion of lease liabilities 369 348 Total current liabilities 1,772 1,562 Lease liabilities, net of current portion 872 1,063 TOTAL LIABILITIES 2,644 2,625 COMMITMENTS AND CONTINGENCIES (Note 8) - - STOCKHOLDERS' EQUITY Preferred stock, $ .001 par value; 5,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024. - - Common stock, $ .001 par value; 40,000,000 shares authorized at June 30, 2025 and December 31, 2024; 10,600,604 and 10,544,691 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 11 11 Additional paid-in capital 153,125 152,906 Accumulated deficit ( 143,537 ) ( 144,332 ) TOTAL STOCKHOLDERS' EQUITY 9,599 8,585 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 12,243 $ 11,210 The accompanying notes are an integral part of these unaudited condensed interim financial statements. 3 NEPHROS, INC. CONDENSED (In thousands, except share and per share amounts) (Unaudited) 2025 2024 2025 2024 Three Months Ended June 30, Six Months Ended June 30, 20

View Full Filing

View this 10-Q filing on SEC EDGAR